Page last updated: 2024-11-04

semustine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5198
CHEMBL ID12948
CHEMBL ID1967746
CHEMBL ID2051944
CHEBI ID6863
SCHEMBL ID4959160
SCHEMBL ID4500
MeSH IDM0019643

Synonyms (130)

Synonym
nsc-95441
nsc135091
33185-87-4
nsc-135091
smr000058889
MLS000069831
DIVK1C_000020
KBIO1_000020
NCI60_042122
SPECTRUM_001335
PRESTWICK_1013
urea, n-(2-chloroethyl)-n'-(4-methylcyclohexyl)-n-nitroso-
nsc95441
1-(2-chloroethyl)-3-(trans-4-methylcyclohexane)-1-nitrosourea
trans-methyl-ccnu
1-(2-choroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea
lomustine, methyl
urea, n-(2-chloroethyl)-n'-(4-methylcyclohexyl)-n-nitroso-, trans-
1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitroso-urea
1-(2-chloroethyl)-1-(((4-methylcyclohexyl)amino)carbonyl)-2-oxohydrazine
urea, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitroso-, trans-
methyl ccnu
meccnu
semustine (usan/inn)
D05822
QTL1_000073
SPECTRUM5_001087
BSPBIO_002571
IDI1_000020
semustinum [inn-latin]
lomustine, methyl-
n-(2-chloroethyl)-n'-(4-methylcyclohexyl)-n-nitrosourea
icig 1110
nci-c04955
semustina [inn-spanish]
urea, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitroso-
nsc 95441
1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea [chloroethyl nitrosoureas]
methyl-ccnu [chloroethyl nitrosoureas]
ccris 6336
n-(2-chloroethyl)-n'-(trans-4-methylcyclohexyl)-n-nitrosourea
semustine [usan:inn]
13909-09-6
C07640
1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea
semustine
methyl-ccnu
MLS001074931
NCGC00095051-01
NCGC00095051-02
nsc 135091
urea, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitroso-, (z)-
urea, n-(2-chloroethyl)-n'-(4-methylcyclohexyl)-n-nitroso-, cis-
cis-1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea
urea, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitroso-, cis-
KBIO2_006951
KBIO2_004383
KBIO3_001791
KBIOGR_001468
KBIO2_001815
KBIOSS_001815
SPECTRUM4_001084
SPECTRUM3_000966
NINDS_000020
SPECTRUM2_000911
SPBIO_000782
SPECTRUM1503422
NCGC00095051-03
me-ccnu
HMS2093E21
nsc-758471
icig-1110
methyl lomustine
chebi:6863 ,
CHEMBL12948
HMS500A22
HMS1922C16
hsdb 7760
unii-6yy7t1t567
6yy7t1t567 ,
semustinum
semustina
egu4cmi14d ,
meccnu (trans)
trans-methyl ccnu
trans-semustine
unii-egu4cmi14d
33073-59-5
1-trans-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea
ai3-52897
nsc758471
pharmakon1600-01503422
dtxsid8031603 ,
tox21_111404
dtxcid6011603
cas-13909-09-6
2281h4fbl9 ,
cis-semustine
unii-2281h4fbl9
cis-methyl ccnu
CHEMBL1967746
1-(2-chloroethyl)-1-([(4-methylcyclohexyl)amino]carbonyl)-2-oxohydrazine
CCG-39897
CHEMBL2051944
semustine, trans-
urea, n-(2-chloroethyl)-n'-(trans-4-methylcyclohexyl)-n-nitroso-
1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, trans-
SCHEMBL4959160
SCHEMBL4500
semustine, cis-
1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea,, cis-
NCGC00095051-04
1-[2-chloroethyl]-3-[4-methylcyclohexyl]-1-nitrosourea
urea, 3-(beta-chloroethyl)-1-(4-methylcyclohexyl)-3-nitroso-
FVLVBPDQNARYJU-UHFFFAOYSA-N
1-(2-chloroethyl)-3-(4-methyl-cyclohexyl)-1-nitrosourea
AB01563283_01
SR-01000763446-2
sr-01000763446
J-007221
SBI-0051825.P002
HY-13747
Q1230937
trans-n-(2-chloroethyl)-n'-(4-methylcyclohexyl)-n-nitroso-urea
Q27277177
CS-0007775
cis-n-(2-chloroethyl)-n'-(4-methylcyclohexyl)-n-nitroso-urea
Q27253629
DTXSID301170045
AKOS040742625

Research Excerpts

Overview

Semustine is an investigational cancer chemotherapeutic agent in widespread use.

ExcerptReferenceRelevance
"Semustine is an investigational cancer chemotherapeutic agent in widespread use. "( Nephrotoxicity of semustine.
Boyd, MR; Kramer, RA; Posada, JG; Weiss, RB, 1983
)
2.04

Treatment

ExcerptReferenceRelevance
"Treatment with Semustine (Methyl-CCNU) resulted in a partial response lasting 15 months."( Response of metastatic cloacogenic carcinoma to treatment with semustine.
Wampler, GL; Zimm, S, 1981
)
0.84

Toxicity

ExcerptReferenceRelevance
" When the dose of methyl-CCNU was further increased to 40 mg kg-1 toxic death occurred, which was, however, significantly reduced by 'priming' with the low dose given."( Priming with low doses of methyl-CCNU reduce the toxicity of high doses of methyl-CCNU and melphalan, and increase the lifespan of mice implanted with Lewis lung carcinoma.
Livnat, I; Perk, K; Zimber, A, 1988
)
0.27
" On closer examination, the agents that appear to be responsible for these especially adverse effects are methotrexate and methyl-CCNU."( Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group.
Begg, CB; Carbone, PP, 1983
)
0.27

Pharmacokinetics

ExcerptReferenceRelevance
" In order to enhance clinical effects of the nitrosoureas, further investigation of the design in therapeutic schedules on the basis of their pharmacokinetic characteristics will be needed."( [Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas].
Wakui, A, 1982
)
0.26
" It was found that the effectiveness of these compounds in producing pharmacokinetic effects correlated directly with their lipophilicity, viz."( Nitroimidazoles as modifiers of nitrosourea pharmacokinetics.
Lee, FY; Workman, P, 1984
)
0.27
" Despite moderately elevated transaminase levels (all cases) and bilirubin levels (three cases), plasma Adriamycin profiles in hepatoma patients were not elevated (terminal half-life of 30 hours) and were indistinguishable from that of non-hepatoma patients with normal liver functions."( Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects.
Bateman, JR; Chan, KK; Chlebowski, RT; Ryden, VM; Tong, MJ; Weiner, JM, 1981
)
0.26

Compound-Compound Interactions

ExcerptReferenceRelevance
"In a randomized multi-institutional trial of the Eastern Cooperative Oncology Group, 316 patients with advanced measurable colorectal adenocarcinoma were treated with a weekly schedule of 5-fluorouracil given orally and intravenously with oral-5-fluorouracil in combination with cyclophosphamide or 6-thioguanine, or with oral Methyl CCNU administered once every eight weeks."( Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-
Carbone, P; Conroy, JF; Douglass, HO; Lavin, PT; Woll, J, 1978
)
0.26
" We conclude that methyl-CCNU may be given with an acceptable level of toxicity in an every 3-week schedule and that the combination of cyclophosphamide, methyl-CCNU, and vincristine warrants further evaluation in the treatment of small cell carcinoma of the lung."( Treatment of small cell carcinoma of the lung using methyl-CCNU (NSC-95441) combined with cyclophosphamide (NSC-26271) and vincristine (NSC-67574) in a 3-week schedule.
Cunningham, TJ; Donavan, MA; Horton, J; Sponzo, RW; Taylor, SG,
)
0.13
" Immunotherapy with VCN-treated membranes was effective only when combined with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU)."( Immunotherapy of L1210 leukemia using neuraminidase-modified plasma membranes combined with chemotherapy.
Brandt, AE; Jameson, AK; Pincus, JH, 1981
)
0.26
"Studies have been conducted on liver microsomal enzymes of B6D2F(1) mice bearing a Day 4 L1210 ascites tumor after treatment with a single intraperitoneal injection of 5-fluorouracil (FUra) alone, and in combination with either cyclophosphamide (CP), methotrexate (MTX), or methyl-CCNU (MeCCNU)."( Studies of the effects of treatment with 5-flourouracil alone and in combination with either cyclophosphamide, methotrexate, or methyl-CCNU on hepatic drug-metabolizing enzymes in murine L1210 leukemia.
Klubes, P; Miller, HG; Trevithick, J, 1980
)
0.26

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Piperidino-CNU and Ethylmethanesulfonato-CNU also effected cures; however, only Piperidino-CNU in one dosage effected a median survival time of greater than 90 days."( Examination of four newly synthesized 2-chloroethylnitrosoureas in comparison with BCNU, CCNU, MeCCNU, chlorozotocin and hydroxyethyl-CNU in preterminal rat leukemia L 5222.
Eisenbrand, G; Fiebig, HH; Zeller, WJ, 1979
)
0.26
" Further, both disease staging and drug dosage have been shown to influence cure rates of combined-modality treatment."( Concepts for treatment of micrometastases developed in murine systems.
Schabel, FM, 1976
)
0.26
" Hematologic toxicity, however, was significantly different, with earlier time to the most severe blood count depressions, more frequent occurrence of severe depression, and a larger percentage of patients requiring dosage reduction on the 6-week regimen."( A randomized comparison of two dosage schedules of methyl CCNU: three-week versus six-week treatments.
DeWys, WD; Khandekar, JD; Kosova, LA; Perlia, CP; Slayton, RE; Taylor, SG; Wolter, J, 1979
)
0.26
" With the dosage and schedule we used, and in our patient population of largely elderly adults, THC therapy resulted in an overall more unpleasant treatment experience than that noted with prochlorperazine or placebo."( Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
Creagan, ET; Frytak, S; Moertel, CG; O'Connell, MJ; O'Fallon, JR; Rubin, J; Schutt, AJ; Schwartau, NW, 1979
)
0.26
" These results showed that the maximum tolerated dosage of the agents administered intrarectally suppressed the development of new tumors after start of the treatment and also the growth of tumors which were detected by endoscopy before the treatment."( Cancer chemotherapy model using autochthonous large bowel cancer in rats.
Kono, K; Narisawa, T; Takahashi, T; Yamaguchi, T, 1978
)
0.26
" The three drugs show similar threshold-type dose-response survival curves on asynchronous cells treated for 1 hr."( A comparison of the lethal effects of three nitrosourea derivatives on cultured human lymphoma cells.
Drewinko, B; Gottlieb, JA; Loo, TL, 1976
)
0.26
"Twenty-one patients with unresectable hepatocellular carcinoma (hepatoma) were treated with adriamycin (15-45 mg/m2 q21 D) and methyl-CCNU (75-150 mg/m2 q 63 D) with dosage adjusted for hepatic dysfunction."( Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects.
Bateman, JR; Chan, KK; Chlebowski, RT; Ryden, VM; Tong, MJ; Weiner, JM, 1981
)
0.26
"A dose-response relation for the cytotoxic activity of chloroethylnitrosourea cancer chemotherapeutic agents in cell culture has been developed."( Quantitative dose-response relations for the cytotoxic activity of chloroethylnitrosoureas in cell culture.
Deen, DF; Weinkam, RJ, 1982
)
0.26
" The results imply that dosage scheduling in the treatment of murine melanomas must be individualized."( Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
Hill, GJ; Hill, HZ, 1982
)
0.26
" Further evaluation of vindesine will require dosage modification."( Sequential phase II studies of chemotherapy for colorectal cancer with 5-fluorouracil and vindesine with or without methyl-1,3 cis(2 chloroethyl)-1-nitrosourea.
Bedikian, AY; Bennetts, RW; Bodey, GP; Karlin, DA; Stroehlein, JR; Valdivieso, M, 1982
)
0.26
" The differences in drug exposure and in cellular chemosensitivity between chambers and tumors suggest caution in the interpretation of drug testing using this system, but the log-linear nature of the dose-response curves is an important feature which may be useful in the eventual development of optimal chemosensitivity testing systems."( Use of the agar diffusion chamber for the exposure of human tumor cells to drugs.
Selby, PJ; Steel, GG, 1982
)
0.26
" Dose-response curves were obtained and the surviving fraction at drug levels estimated to be achieved in man was used as a measure of in vitro drug sensitivity."( In vitro chemosensitivity tests on xenografted human melanomas.
Bateman, AE; Selby, PJ; Steel, GG; Towse, GD, 1980
)
0.26
" Preoperative radiotherapy with a dosage of 35-45 Gy can lead to downstaging of rectal cancer."( [Developments up to now and current status of adjuvant chemo- and radiotherapy in colonic and rectal carcinoma].
Eble, MJ; Kraus, TW; Raeth, U, 1994
)
0.29
" Chemotherapy consisted of: (1) up to six cycles of the standard CHOP based regimen, or (2) up to six cycles of the standard CHOP based regimen with oral Semustine dosed at 120 mg (or Lomustine dosed at 100mg) on day 1 of each chemotherapy cycle."( Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo, Y; Hong, X; Li, J; Li, X; Lu, JJ; Ma, X; Wang, B, 2008
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
alkylating agentHighly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
N-nitrosoureasA nitroso compound that is any urea in which one of the nitrogens is substituted by a nitroso group
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency32.19680.007215.758889.3584AID624030
BRCA1Homo sapiens (human)Potency5.01190.89137.722525.1189AID624202
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686979
AR proteinHomo sapiens (human)Potency23.71010.000221.22318,912.5098AID743042; AID743054
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency12.58930.011212.4002100.0000AID1030
pregnane X nuclear receptorHomo sapiens (human)Potency11.22020.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency16.51410.000229.305416,493.5996AID743079; AID743080; AID743091
aryl hydrocarbon receptorHomo sapiens (human)Potency10.90470.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency9.43920.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency5.01190.10009.191631.6228AID1346983
DNA polymerase eta isoform 1Homo sapiens (human)Potency100.00000.100028.9256213.3130AID588591
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency20.31480.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency12.58930.125912.234435.4813AID1458
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency29.84930.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency29.84930.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)4.80900.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki1.80300.00010.807410.0000AID625201
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (60)

Processvia Protein(s)Taxonomy
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (61)

Assay IDTitleYearJournalArticle
AID1149527Antitumor activity against mouse advanced Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as increase in host lifespan administered as single dose on day 6 or 7 post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID134226Toxicity against L-1210 leukemia cells in mice after intraperitoneal administration, activity is expressed as LD101980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID1149525Antitumor activity against mouse advanced Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as complete regression of established tumor administered as single dose on day 6 or 7 post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID23276Partition coefficient (logP)1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID3299Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthesis of nitrosourea derivatives of pyridine and piperidine as potential anticancer agents.
AID3295Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16)1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthesis of nitrosourea derivatives of pyridine and piperidine as potential anticancer agents.
AID3298Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthesis of nitrosourea derivatives of pyridine and piperidine as potential anticancer agents.
AID102369Antitumor effect against MAC15A Tumors was determined by the percent of mean weight of treated tumors to mean weight of control tumors by saline at dose 20 mg/kg1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Nucleoside analogs. 14. The synthesis of antitumor activity in mice of molecular combinations of 5-fluorouracil and N-(2-Chloroethyl)-N-nitrosourea moieties separated by a three-carbon chain.
AID102224Antitumor effect against MAC13 Tumors was determined by the percent of mean weight of treated tumors to mean weight of control tumors by 10% ethanol/arachis oil at dose 20 mg/kg1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Nucleoside analogs. 14. The synthesis of antitumor activity in mice of molecular combinations of 5-fluorouracil and N-(2-Chloroethyl)-N-nitrosourea moieties separated by a three-carbon chain.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID102235Antitumor effect against MAC13 Tumors was determined by no. deaths/treated of mice by 10% ethanol/arachis oil at dose 20 mg/kg; no of deaths/treated 0/51996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Nucleoside analogs. 14. The synthesis of antitumor activity in mice of molecular combinations of 5-fluorouracil and N-(2-Chloroethyl)-N-nitrosourea moieties separated by a three-carbon chain.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID3297Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6)1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthesis of nitrosourea derivatives of pyridine and piperidine as potential anticancer agents.
AID681018TP_TRANSPORTER: inhibition of PAH uptake (PAH: 20 uM, Semustine: 300 uM) in OAT-expressing COS-7 cells1999The Journal of biological chemistry, Jan-15, Volume: 274, Issue:3
Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1123689Toxicity in mouse allografted with mouse L1210 cells assessed as survival at 12.5 mg/kg1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1149526Antitumor activity against mouse advanced Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as disease cure administered as single dose on day 6 or 7 post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1133740Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
AID1123687Antitumor activity against mouse L1210 cells allografted in mouse assessed as tumor growth inhibition at 12.5 mg/kg relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1123686Antitumor activity against mouse L1210 cells allografted in mouse assessed as tumor growth inhibition at 25 mg/kg relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1133739Therapeutic index, ratio of LD10 for BDF1 mouse to ED50 for mouse L1210 cells allografted in ip dosed BDF1 mouse1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
AID1123667Toxicity in mouse allografted with mouse L1210 cells assessed as survival at 50 mg/kg1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1133737Toxicity in ip dosed BDF1 mouse1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
AID125581Tested for 3 log kill of leukemia cells1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID1123677Toxicity in mouse allografted with mouse L1210 cells assessed as change in body weight at 12.5 mg/kg relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1123675Toxicity in mouse allografted with mouse L1210 cells assessed as change in body weight at 50 mg/kg relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1123674Toxicity in mouse allografted with mouse L1210 cells assessed as change in body weight at 100 mg/kg relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1149385Antitumor activity against mouse advanced Lewis lung carcinoma allografted in BDF1 mouse assessed as increase in host life span at 36 mg/kg, ip administered as single dose on 7th day post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1149521Antitumor activity against mouse early Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as disease cure administered as single dose on 1 or 2 days post-tumor implantation measured for 80 days post-drug treatment1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1123678Toxicity in mouse allografted with mouse L1210 cells assessed as change in body weight at 6.25 mg/kg relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1123688Antitumor activity against mouse L1210 cells allografted in mouse assessed as tumor growth inhibition at 6.25 mg/kg relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1149523Ratio of ED50 for antitumor activity against mouse L1210 cells allografted in ip dosed mouse to LD10 for mouse1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1149472Antitumor activity against mouse early Lewis lung carcinoma allografted in BDF1 mouse assessed as increase in host life span at 24 mg/kg, ip administered as single dose on 1 or 2 days post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1149500Antitumor activity against mouse early Lewis lung carcinoma allografted in BDF1 mouse assessed as time delay in tumor growth at 24 mg/kg, ip administered as single dose on 1 or 2 days post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1133738Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as increase of life span of host measured up to 45 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
AID1123676Toxicity in mouse allografted with mouse L1210 cells assessed as change in body weight at 25 mg/kg relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1123685Antitumor activity against mouse L1210 cells allografted in mouse assessed as tumor growth inhibition at 50 mg/kg relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1123668Toxicity in mouse allografted with mouse L1210 cells assessed as survival at 25 mg/kg1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1123690Toxicity in mouse allografted with mouse L1210 cells assessed as survival at 6.25 mg/kg1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1149499Antitumor activity against mouse early Lewis lung carcinoma allografted in BDF1 mouse assessed as time delay in tumor growth at 36 mg/kg, ip administered as single dose on 1 or 2 days post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1123684Antitumor activity against mouse L1210 cells allografted in mouse assessed as tumor growth inhibition at 100 mg/kg relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
AID1149471Antitumor activity against mouse early Lewis lung carcinoma allografted in BDF1 mouse assessed as increase in host life span at 36 mg/kg, ip administered as single dose on 1 or 2 days post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (468)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990372 (79.49)18.7374
1990's44 (9.40)18.2507
2000's22 (4.70)29.6817
2010's26 (5.56)24.3611
2020's4 (0.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.98 (24.57)
Research Supply Index6.47 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials152 (30.83%)5.53%
Reviews54 (10.95%)6.00%
Case Studies19 (3.85%)4.05%
Observational0 (0.00%)0.25%
Other268 (54.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Outcomes of Patients After Allogenic Hematopoietic Cell Transplantation With Decitabine-containing Conditioning Regimen and Acetylcysteine Treatment [NCT04945096]Phase 3100 participants (Anticipated)Interventional2021-07-01Not yet recruiting
Reduced Intensity Conditioning Regimen for Low- and Intermediate-risk Myelodysplastic Syndrome Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation [NCT03412266]Phase 250 participants (Anticipated)Interventional2018-02-01Recruiting
A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma [NCT00335075]Phase 3151 participants (Actual)Interventional2005-03-02Completed
A Clinical Trial to Evaluate Postoperative Immunotherapy and Postoperative Systemic Chemotherapy in the Management of Resectable Colon Cancer [NCT00427570]Phase 30 participants Interventional1977-09-30Completed
A Randomized Controlled Study on the Efficacy and Safety of MA-BUCY2 Protocol in the Conditioning of Haploidentical Stem Cell Transplantation in Patients With High-risk Acute Myeloid Leukemia [NCT05814731]264 participants (Anticipated)Interventional2023-04-15Not yet recruiting
Reduced Intensity Conditioning Regimen for Elderly or High Comorbidity Burden Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation [NCT03412409]Phase 250 participants (Anticipated)Interventional2018-02-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]